Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2010. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding their interests in the company's Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a disclosure of share transactions and does not contain financial performance data.
Material Changes
The material change disclosed is the acquisition of Ordinary shares by eight individuals on July 9, 2010, through the Company's Share Reward Plan. The purchase price was £11.25 per Ordinary share. Each individual acquired 11 shares under the partnership element (personal contribution) and 11 shares under the matching element (Company contribution), except for Mr. P J T Vallance, whose entries were listed in reverse order but reflect the same quantities.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on business strategy, risks, contingencies, or unusual items. It is a regulatory compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the share price of £11.25 per Ordinary share on July 9, 2010.
- Confirm the total number of shares acquired by each named director (22 shares per person: 11 personal, 11 company match).
- Review the specific terms of the Company's Share Reward Plan to understand the matching mechanism.
- Note that this filing does not reflect broader company financial performance for the period.